Colitis - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 108
Inquire Before Buying

Colitis - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H2 2018, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 3, 20 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.

Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Colitis - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Colitis - Overview
Colitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Colitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Colitis - Companies Involved in Therapeutics Development
Akebia Therapeutics Inc
Apollo Endosurgery Inc
Bristol-Myers Squibb Co
Concenter BioPharma Silkim Ltd
Cosmo Pharmaceuticals NV
Dr. Falk Pharma GmbH
EA Pharma Co Ltd
Genfit SA
Immuron Ltd
Inflazome Ltd
Ogeda SA
Pfizer Inc
RDD Pharma Ltd
Saniona AB
Soligenix Inc
Sublimity Therapeutics Ltd
Vitality Biopharma Inc
Colitis - Drug Profiles
AcTMP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKB-6899 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AN-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APY-0201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BC-1215 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSA-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimethyloxalylglycine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dusquetide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elafibranor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ESN-601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate PD-L1 for Colitis and Graft Versus Host Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GFC-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-124E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAK-11049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCC-950 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit LTC4 for Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06425090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDD-2007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifamycin CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-182 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Colitis and Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Colitis and Crohn's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYMB-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPC-1022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-303 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Colitis - Dormant Projects
Colitis - Discontinued Products
Colitis - Product Development Milestones
Featured News & Press Releases
May 10, 2018: Vitality's GI-targeted VBX-100 THC compound to be investigated as treatment of recurrent difficile infections
May 07, 2018: Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program
Feb 05, 2018: Tillotts Pharma announces MHRA approval of Entocort Capsules for Microscopic Colitis
Feb 05, 2018: Tillotts Pharma announces MHRA approval of Entocort Capsules for Microscopic Colitis
Jul 19, 2017: Vitality Biopharma Releases Positive Results for Treatment of Inflammatory Bowel Disease
Apr 18, 2017: Immuron Announces Positive Results of IMM-124E in Acute Colitis Research Studies
Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Colitis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Colitis - Pipeline by Akebia Therapeutics Inc, H2 2018
Colitis - Pipeline by Apollo Endosurgery Inc, H2 2018
Colitis - Pipeline by Bristol-Myers Squibb Co, H2 2018
Colitis - Pipeline by Concenter BioPharma Silkim Ltd, H2 2018
Colitis - Pipeline by Cosmo Pharmaceuticals NV, H2 2018
Colitis - Pipeline by Dr. Falk Pharma GmbH, H2 2018
Colitis - Pipeline by EA Pharma Co Ltd, H2 2018
Colitis - Pipeline by Genfit SA, H2 2018
Colitis - Pipeline by Immuron Ltd, H2 2018
Colitis - Pipeline by Inflazome Ltd, H2 2018
Colitis - Pipeline by Ogeda SA, H2 2018
Colitis - Pipeline by Pfizer Inc, H2 2018
Colitis - Pipeline by RDD Pharma Ltd, H2 2018
Colitis - Pipeline by Saniona AB, H2 2018
Colitis - Pipeline by Soligenix Inc, H2 2018
Colitis - Pipeline by Sublimity Therapeutics Ltd, H2 2018
Colitis - Pipeline by Vitality Biopharma Inc, H2 2018
Colitis - Dormant Projects, H2 2018
Colitis - Dormant Projects, H2 2018 (Contd..1), H2 2018
Colitis - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Colitis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Esomeprazole Market Research Report 2018
    Published: 13-Jul-2018        Price: US 2900 Onwards        Pages: 93
    This report studies the global Esomeprazole market status and forecast, categorizes the global Esomeprazole market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Esomeprazole market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. The major man......
  • 2018-2023 Global Gastrointestinal Consumption Market Report
    Published: 12-Jul-2018        Price: US 4660 Onwards        Pages: 164
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Gastrointestinal market for 2018-2023. Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders. The global average gross margin of Gast......
  • 2018 Top 5 Gastrointestinal Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 12-Jul-2018        Price: US 4960 Onwards        Pages: 145
    Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders. The global average gross margin of Gastrointestinal is in a slight decreasing trend, and the gross margin is 63% in 2015. Europe region is the largest supplier of Gastrointestinal, with a production revenue marke......
  • Hepatic Encephalopathy - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 72
    Hepatic Encephalopathy - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Pipeline Review, H2 2018, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape. Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. Symptoms include disorientation, dro......
  • Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 35
    Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018, provides an overview of the Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline landscape. Non-ulcer dyspepsia is a term used to describe signs and symptoms of indigestion that have no obvious cause. Non-ulcer dyspepsia is also called func......
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 91
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atypical Hemolytic Uremic Syndrome - Pipeline Review, H2 2018, provides an overview of the Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline landscape. Atypical hemolytic uremic syndrome is a disease that primarily affects kidney function. T......
  • Primary Sclerosing Cholangitis - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 111
    Primary Sclerosing Cholangitis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H2 2018, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape. Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the......
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 83
    Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis - Pipeline Review, H2 2018, provides an overview of the Reflux Esophagitis (Gastrointestinal) pipeline landscape. When the liquid content of the stomach refluxes into the esophagus, that condition is called Gastro esophageal reflux disease (GERD). It is a chronic condi......
  • Diarrhea - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 153
    Diarrhea - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Pipeline Review, H2 2018, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape. Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs